China’s Walking Exoskeletons: What Buyers Need to Verify

A walking exoskeleton can look convincing in a short demonstration. The harder purchasing decision comes afterwards: who is supposed to wear it, what must that person already be able to do, and what has actually been tested?

China’s public product material spans clinical rehabilitation, everyday assistance and outdoor use. Similar-looking hardware can therefore lead to very different procurement decisions. This note separates those use cases and the evidence behind them. It is an exploratory category study, not a qualified-supplier list or an expansion into clinical assessment services.

Three use cases, different evidence questions

These are buyer-facing distinctions, not three legal classifications. Everyday walking and outdoor recreation can overlap; the exact intended use matters more than the category label.

Clinical rehabilitation. Start with the proposed therapeutic purpose, eligible users, setting and supervision. In the United States, 21 CFR 890.3480 defines a prescription powered lower-extremity exoskeleton for medical purposes and places that category in Class II with special controls. It does not establish that a named Chinese product is cleared for sale or that every consumer wearable belongs in that category. Source 1

Everyday walking assistance. A product may be offered to assist a movement without a treatment claim. Ask whether users must already stand, walk and balance independently. Reduced effort, independent mobility and fall prevention are different outcomes; evidence for one should not be substituted for another.

Outdoor use. Hypershell’s X-series page positions the product as nonmedical and says it requires unassisted walking and balance. That manufacturer statement helps identify its proposed user; it is not a clinical assessment or a regulatory opinion. A successful hiking demonstration would not establish suitability for someone with substantial mobility impairment. Source 2

For a distributor, these distinctions affect fitting, instructions, training, support and the claims that can responsibly be made to customers.

What the Chinese examples establish

RoboCT’s company timeline says it launched the GoGo series in 2025, following earlier rehabilitation-oriented development. Treat that as company history, not independently verified clinical performance. Its public marketing is a starting point for a model-specific document request. Source 3

A separate Xinhua report, dated 18 March 2025, described a RoboCT battery-free walking-assistance design ahead of launch. The supplied SCIO link is a republication dated the following day. We use the accessible Xinhua original. Do not assume that the historical passive design and a currently advertised powered model are interchangeable, or that an old launch price is a current quotation. Source 4

Hangzhou’s information portal reported on the AsExo-TK1000 “Tashan” on 8 January 2026, identifying its developer as China South Industries Group Corporation’s Zhiyuan Research Institute in Hangzhou. The report describes hip and waist support. Its performance and price statements remain reported product claims; we have not obtained the underlying tests or current commercial documentation. Source 5

On 13 January 2026, the State Council’s English website reported guidelines that explicitly mention exoskeletons and muscle suits for older people with declining physical function. That establishes policy interest. It does not establish sales, routine use or suitability for a particular buyer. Source 6

Read the research at the right level

A July 2026 feasibility study enrolled ten older adults. Its prototype produced 1.8 more one-minute sit-to-stand repetitions on average; walking metabolic analysis in nine participants reported a 13.6% mean reduction. The comparison was assistance on versus off while wearing the suit, not against wearing no device. Source 7

These are short-term, task-specific results. They do not show that the Chinese products discussed here deliver the same effects, or establish fewer falls, lower care costs or long-term independent living. A device that helps during a supervised task also raises a separate question: does any improvement persist after it is removed?

A 2026 knee-exoskeleton systematic review highlights heterogeneous devices, limited clinical samples and uncertain lasting rehabilitation gains. Its findings should not be transferred wholesale to hip-assistance products. Source 8

Five questions for an international buyer

Use a written evidence request before comparing quotations. Keep the legal entity, exact model, configuration, source and check date alongside each answer.

The interruption questions need to match the mechanism: a passive device has no low-battery mode, but its removal, mechanical behavior and use restrictions still need investigation. Do not perform unsupervised safety experiments on a person to fill an evidence gap.

Download the editable exoskeleton buyer-question worksheet (CSV). It records answers and unresolved issues; completing it is not product approval. For a general evidence method, read Supplier Claims vs. Verified Evidence.

A sourcing opportunity still needs a service model

Lighter, more specific assistance could create useful product propositions. That remains a business hypothesis until a buyer can establish a suitable user group, supportable claims, workable distribution economics and reliable local service.

A compelling demonstration does not answer questions about prolonged comfort, fit across body types, returns, maintenance or total ownership cost. Assess the service obligations around the device as carefully as the hardware. At this stage, a clear unresolved question is more useful than a premature “verified” label.

Research approach and limits

Checked on 30 October 2026 using public product pages, original reporting, current regulatory text and accessible research. Publisher-indexed Nature text was available through search, while direct retrieval redirected to its identity service. Social-video metadata informed the lead register only: none of the six supplied clips was visually verified or included as evidence of performance. We have not tested products, audited factories or verified product-specific market authorization. This is industry research, not medical advice or a product endorsement.